Jun. 4 at 4:08 PM
$NWBO https://sg.finance.yahoo.com/news/booking-health-announces-release-findings-203800814.html
Sounds like it was DCVAX:
"Dendritic cells are the immune system's most powerful antigen-presenting cells that identify threats and instruct T-cells on how to attack them. In the context of dendritic vaccine manufacturing, a patient's blood is drawn, monocytes are isolated and matured into dendritic cells in a laboratory. Those cells are then loaded with tumor-associated antigens — and reinjected into the patient. The goal is to train the immune system to recognize and target the tumor.
A landmark 2019 study published in Nature demonstrated that dendritic cell vaccination + standard care produced a meaningful survival advantage in GBM patients...
... a Phase 3 trial published in JAMA confirms that immunotherapy approaches, including dendritic cell-based strategies, are among the most actively studied frontiers in neuro-oncology, precisely because the biological rationale is sound and the side effect profile is categorically different from cytotoxic therapy."
